Skip to main content
. 2025 Dec 19;12(1):129–139. doi: 10.1159/000549112

Table 1.

General data of 302 patients on MHD

Characteristic Without PH and HVC (n = 138) With PH or HVC (n = 121) With PH and HVC (n = 43)
Age, years 66 (56.0, 75.0) 60 (49.5, 71.0)a 57 (45.0, 71.0)a
Male/female ratio 75/63 62/59 25/18
Age of initial dialysis, years 57.3 (43.5, 69.3) 62.0 (50.5, 71.2) 62.7 (55.3, 71.3)
Systolic BP, mm Hg 148±22 149±25 157±27a
Diastolic BP, mm Hg 77±15 75±18 74±16
Body mass index, kg/m2 21.5±3.0 21.3±3.1 20.9±3.0
Diabetes, n (%) 40 (29.0) 44 (36.4) 18 (41.9)
Hypertension, n (%) 130 (94.2) 109 (90.1) 40 (90.3)
Causes of CKD, n (%)
 Primary glomerular diseases 52 (37.7) 29 (24.0) 9 (20.9)
 Hypertensive nephrosclerosis 35 (25.4) 34 (28.1) 12 (27.9)
 Diabetes nephropathy 28 (20.3) 34 (28.1) 15 (34.9)
 Obstructive nephropathy 6 (4.3) 15 (12.4) 5 (11.6)
 Others 17 (12.3) 9 (7.4) 2 (4.7)
Previous history of CVD, n (%) 42 (30.4) 33 (27.3) 16 (37.2)
 Angina pectoris 15 (10.9) 10 (8.3) 6 (14.0)
 Acute myocardial infarction 3 (2.2) 2 (1.7) 2 (4.7)
 Cerebral infarction 19 (13.8) 10 (8.3) 9 (20.9)
 Cerebral hemorrhage 5 (3.6) 1 (0.8) 2 (4.7)
 Sudden death 2 (1.4) 1 (1.8) 0
 Acute heart failure 10 (7.2) 12 (9.9) 4 (9.3)
 Severe arrhythmia 4 (2.9) 5 (4.1) 3 (7.0)
 Transient ischemic attack 2 (1.4) 3 (2.4) 1 (2.3)
Charlson rating (≥1), n (%) 41 (29.7) 44 (36.4) 19 (44.2)
 1 28 (20.2) 23 (19.0) 14 (32.6)
 2 9 (6.5) 12 (9.9) 5 (11.6)
 ≥3 4 (2.9) 9 (7.4) 0
Valve reg. mod-severe, n (%) 13 (9.4) 48 (40.0)a 25 (58.1)a,b
LVEF, % 65±7 61±13a 62.1±13
Vascular access for AVF, n (%) 105 (76.1) 110 (90.9)a 39 (90.7)a
UFR, mL/kg/h 10.9±4.9 11.1±4.4 11.2±3.9
Antihypertensive drug use, n (%)
 Calcium antagonists 88 (63.8) 82 (67.8) 31 (72.1)
 ACEI or ARB 59 (42.8) 62 (51.2) 22 (51.2)
 ACEI and ARB 13 (9.4) 7 (5.8) 4 (9.3)
 Beta-blocker 77 (55.8) 62 (51.2) 23 (53.5)
 Alpha receptor blocker 46 (33.3) 48 (40.0) 23 (53.5)

BP, blood pressure; valve reg. mod-severe, moderate-to-severe valvular regurgitation; LVEF, left ventricular ejection fraction; AVF, arteriovenous fistula; UFR, ultrafiltration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

a p < 0.05 compared to 0-risk factor group.

b p < 0.05 compared to 1-risk factor group.